Clinical trials: in Kenya
Diarrhoea
A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants
This study evaluates the immune response and safety of a multicomponent, 2-dose Shigella vaccine in preventing shigellosis in African infants.
- Trial name
- NCT06663436
- Testing
- altSonflex1-2-3 Dose A, altSonflex1-2-3 Dose B, altSonflex1-2-3 Dose C
- Where
- Kenya
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer, HPV
Elimisha HPV (Human Papillomavirus)
This research study aims to develop a stigma-responsive educational intervention which includes simplified scripts that provide clear messages about HPV and video aimed at addressing fears and misperceptions from a peer…
- Conditions
- Cervical Cancer, HPV, HIV, Stigma
- Trial name
- NCT05736588
- Testing
- Elimisha HPV
- Where
- Kenya
- Volunteers
- 963 people, healthy volunteers welcome
- Sponsor
- Duke University
HIV
IBIS Megastudy- Pilot
In this pilot study, the investigators will determine the feasibility and acceptability of multiple low-cost behavioral interventions, designed with end-user input, to promote HIV retesting among adults in rural Kenya and Uganda…
- Trial name
- NCT06785103
- Testing
- Risk assessment messaging, U=U messaging, Healthy Living messaging
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
HIV
SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension
The overall purpose of this SEARCH CAB-LA (Cabotegravir Injectable Suspension) randomized extension study is to determine if adding the option of CAB-LA as a prevention choice using a person-centered dynamic choice HIV (human…
- Trial name
- NCT05549726
- Testing
- Cabotegravir Injectable Suspension, Dynamic Choice Delivery Model, Standard of Care
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 984 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Human Immunodeficiency Virus, STI
A Savings Intervention to Reduce Men's Engagement in HIV Risk Behaviors
This randomized control trial will test an economic intervention to reduce Kenyan men's engagement in behaviors that increase the risk of HIV/STIs.
- Conditions
- Human Immunodeficiency Virus, STI, Alcohol Consumption, Incentives
- Trial name
- NCT05385484
- Testing
- Receives mobile banking account with incentives to save, Basic Health and financial education
- Where
- Kenya
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
HIV Prevention, HIV Preexposure Prophylaxis
Social Media as a Risk Tool for HIV Prevention Needs
The impact of effective HIV prevention tools is limited because many people do not know that they are at risk for HIV acquisition, despite the availability of various risk assessment scores and criteria.
- Trial name
- SMaaRT (NCT06566417)
- Where
- Kenya
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Autism
Expanding Autism Diagnostic Biomarkers to Kenya
The study will use a non-invasive remote eye-tracking system (Eyelink Portable Duo) to acquire a short series of eye-tracking measures.
- Trial name
- KinleyET (NCT06685822)
- Testing
- Eyelink Portable Duo
- Where
- Kenya
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Indiana University
Violence, Domestic, Violence, Sexual
Dissemination and Implementation of a Web-based Relationship Safety App, myPlanKenya, for Women at Risk for Intimate Partner Violence in Nairobi, Kenya
This effectiveness-implementation hybrid-3 study evaluates dissemination, implementation, and effectiveness of myPlanKenya. myPlanKenya will be disseminated through formal and informal sectors.
- Conditions
- Violence, Domestic, Violence, Sexual, Violence, Gender-Based
- Trial name
- myPlanKenya (NCT05609786)
- Testing
- Personalized safety planning tool
- Where
- Kenya
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Diarrhoea
A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants
The aim of the current clinical study was to evaluate, for the first time in humans (FTIH), the safety and immunogenicity of the altSonflex1-2-3 candidate vaccine against S. sonnei and S. flexneri serotypes 1b, 2a, and 3a.
- Trial name
- NCT05073003
- Testing
- AltSonflex1-2-3 High Dose, AltSonflex1-2-3 Medium Dose, AltSonflex1-2-3 Low Dose
- Where
- 2 sites in Belgium, Kenya
- Volunteers
- 551 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections
The Women TAF-FTC Benchmark Study
The study seeks to assess the safety of and define blood and tissue benchmark concentrations of tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in cisgender women using directly observed oral pre-exposure…
- Trial name
- NCT05140954
- Testing
- co-formulated 25mg TAF/ 200mg FTC
- Where
- Kenya
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Washington
HIV Infections
The Women TDF-FTC Benchmark Study
The study seeks to define the expected blood levels of pre-exposure prophylaxis (PrEP) medications (tenofovir) for cisgender women taking directly observed oral PrEP therapy to understand the frequency of PrEP dosing associated…
- Trial name
- NCT05057858
- Testing
- co-formulated 300 mg TDF/ 200mg FTC
- Where
- Kenya
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Washington
COVID-19
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
The purpose of this Phase III study is to assess the efficacy, safety, and immunogenicity of two CoV2 preS dTM-AS03 vaccines (monovalent and bivalent) as part of primary series vaccinations in a multi-stage approach, as well as a…
- Trial name
- VAT00008 (NCT04904549)
- Testing
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent D614) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (bivalent D614 + B.1.351) (primary series), SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent B.1.351) (booster dose) >= 4 months after last vaccination
- Where
- 86 sites in United States, Colombia and 9 more
- Volunteers
- 23,670 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Violence, Domestic, Psychological Distress
Adapting a Low-cost Intimate Partner Violence and Mental Health Response Intervention
The goal of this feasibility study (clinical trial) is to test a low-cost, combined, adapted intimate partner violence (IPV) and mental health intervention (Wings of Hope: WINGS + Problem Management Plus: PM+) that can be carried…
- Trial name
- NCT06350383
- Testing
- WINGS+PM+, PM+-only
- Where
- 2 sites in Kenya
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Columbia University
HIV/AIDS
The Outreach and Prevention at ALcohol Venues in East Africa Study (OPAL-East Africa- Aim 1)
This study will test innovative interventions to increase uptake and use of biomedical HIV prevention options by engaging women and men at drinking venues in rural Kenya and Uganda in care, while gaining insights into the…
- Trial name
- OPAL-Aim 1 (NCT05862857)
- Testing
- HIV-focused mobilization, Multi-disease-focused mobilization
- Where
- 2 sites in Kenya, Uganda
- Volunteers
- 9,375 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Mother to Child Transmission, Pregnancy in Adolescence
Digital Intervention to Address Stigma Among Pregnant Adolescents Living With HIV
Pregnant adolescents living with HIV (ALHIV) in Kenya frequently experience stigma and difficulty telling a family member about their HIV and pregnancy status.
- Conditions
- Mother to Child Transmission, Pregnancy in Adolescence, Social Stigma, Self Disclosure
- Trial name
- NCT05383755
- Testing
- Digital intervention for pregnant adolescents living with HIV
- Where
- Kenya
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Pacific Institute for Research and Evaluation
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers
The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by…
- Trial name
- NCT04588428
- Testing
- INO-4700, CELLECTRA™ 2000
- Where
- 6 sites in Jordan, Kenya and 1 more
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
HIV Prevention
Peer PrEP Referral + HIV Self-test Delivery for PrEP Initiation in Kenya
Few young women at risk of HIV infection are initiating pre-exposure prophylaxis (PrEP) for HIV prevention in Kenya, thus we propose refining and testing a new model to increase PrEP initiation among young women at high HIV risk…
- Trial name
- PeerPrEP (NCT04982250)
- Testing
- Enhanced peer PrEP referral + HIVST delivery
- Where
- Kenya
- Volunteers
- 211 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Risk Reduction
Point-of-care Urine Monitoring of Adherence: Testing a Real-Time Urine Assay of Tenofovir in PrEP
Worldwide expansion of pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) will be critical to ending the HIV epidemic.
- Trial name
- PUMA (NCT03935464)
- Testing
- PUMA
- Where
- Kenya
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Infection, Malaria
Anti-malaria MAb in Kenyan Children
The purpose of this study is to evaluate the safety and tolerability of one-time subcutaneous (SC) administration of monoclonal antibody (MAb) L9LS in healthy Kenyan children aged 5 months to 10 years, as well as the protective…
- Trial name
- NCT05400655
- Testing
- L9LS
- Where
- Kenya
- Volunteers
- 912 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women
This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in…
- Trial name
- NCT03164564
- Testing
- Oral CAB, Oral TDF/FTC, CAB LA
- Where
- 20 sites in Botswana, Eswatini and 5 more
- Volunteers
- 3,224 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)